Global Krabbe disease treatment market tipped to grow

The worldwide Krabbe disease treatment market has been tipped to experience growth in the coming years.

According to estimates from Technavio, the market is expected to grow at a compound annual growth rate of more than seven percent between 2018 and 2022.

A report by the organisation believes this will be fuelled by the assignment of special drug designations to drugs and biologics that are intended for the safe and effective treatment of Krabbe disease.

Technavio also highlighted a notable trend in the global Krabbe disease treatment market – the emergence of pharmacological chaperone therapy. 

More than two-fifths of the known cases of Krabbe disease were said to be because of the missense mutation in the GLC enzyme, which result in the disruption of enzyme folding, stopping the GLC from reaching its site of action in sufficient quantities in the lysosome. 

While the strategies for treatment of other lysosomal storage disorders are ineffective in treating Krabbe disease, pharmacological chaperone therapy targets misfolded GLC after identifying molecules that can stabilise the enzyme by binding to the site. 

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.